Humacyte Inc (HUMA) - News Archive

In an exceptional showcase of innovation and scientific advancement, Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology company dedicated to the development of bioengineered human tissues, has announced its parti...

Humacyte, Inc. Prices $50 Million Stock Offering Amid Recent Growth in Share PriceDURHAM, N.C. Humacyte, Inc. (Nasdaq: HUMA), a biotechnology firm specializing in the development of bioengineered human tissues for medic...

In a significant advancement for vascular medicine, Humacyte Inc. has secured FDA approval for its innovative product, SYMVESS, an acellular tissue-engineered vessel designed specifically to treat extremity vascular tra...

Revolutionary Advances in Vascular Repair: Humacyte s ATEV and BVP Programs Presented in JAMA SurgeryIn a landmark publication, Humacyte Inc. announced its innovative Acellular Tissue Engineered Vessel (ATEV) has demons...

Humacyte Inc.: Navigating Legal Challenges and Stagnant Revenue Growth in the Biopharmaceutical Landscape In recent developments concerning Humacyte Inc. a class action lawsuit has been filed against the company in the...

Humacyte, Inc. (NASDAQ: HUMA) has found itself at the center of significant legal and operational challenges following the filing of a shareholder class action lawsuit. The lawsuit has brought to light critical issues r...

In a significant development for its growth trajectory, Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology firm based in Durham, North Carolina, has entered into a securities purchase agreement with an institutio...

Advancements in Vascular Access for Hemodialysis: Humacyte’s Bioengineered Vessels in the Spotlight at ASN Kidney Week 2024 In the continuing quest to enhance medical outcomes for patients with end-stage renal disease (...

DURHAM, N.C. Oct. 4, 2024 In a significant move for its financial future, Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology platform specializing in the development of universally implantable, bioengineered huma...

Breakthrough in Hemodialysis: Humacyte s Acellular Tissue Engineered Vessel Outperforms Standard Fistula in Phase 3 TrialIn a significant advancement in the realm of hemodialysis access, Humacyte has unveiled the promis...

In recent years, Humacyte Inc., a clinical-stage biotechnology platform company, has garnered significant attention for its groundbreaking advancements in bioengineered human tissues. This article aims to interpret seve...

The development of effective treatments for type 1 diabetes continues to be a significant focus in medical research. Recently, Humacyte presented positive preclinical data showcasing their BioVascular Pancreas (BVP) pro...

The Centers for Medicare & Medicaid Services (CMS) recently announced the issuance of four distinct ICD-10-PCS codes, effective from October 1, 2024. These codes are specifically designated for the replacement of arteri...

DURHAM, N.C., Feb. 29, 2024 - Humacyte, Inc. (Nasdaq: HUMA), a renowned clinical-stage biotechnology platform company, has announced the initiation of an underwritten public offering of its common stock. This strategic...

Human Acellular Vessel (HAV) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular TraumaBLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-w...

Humacyte Submits BLA to U.S. FDA for Human Acellular Vessel (HAV) - A Revolutionary Treatment for Vascular TraumaBLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a h...